BACKGROUND: Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic acid administration during early pregnancy, whereas NTDs in other mutants are not prevented. This parallels human NTDs, in which up to 30% of cases may be resistant to folic acid. Most spina bifida cases in the folic acidresistant 'curly tail' mouse can be prevented by treatment with inositol early in embryonic development. Here, the effectiveness and safety during pregnancy of two isomers, myo-and D-chiro-inositol, in preventing mouse NTDs was compared. METHODS AND RESULTS: Inositol was administered either directly to embryos in vitro, or to pregnant females by s.c. or oral routes. Although D-chiro-and myo-inositol both reduced the frequency of spina bifida in curly tail mice by all routes of administration, D-chiro-inositol consistently exhibited the more potent effect, reducing spina bifida by 73-86% in utero compared with a 53-56% reduction with myo-inositol. Pathological analysis revealed no association of either myo-or D-chiro-inositol with reduced litter size or fetal malformation. CONCLUSIONS: D-chiro-inositol offers a safe and effective method for preventing folic acid-resistant NTDs in the curly tail mouse. This raises the possibility of using inositol as an adjunct therapy to folic acid for prevention of NTDs in humans.
Introduction
Folic acid supplementation during early pregnancy can prevent a proportion of neural tube defects (NTDs) (Wald et al., 1991; Czeizel and Dudás, 1992; Berry et al., 1999) , whereas other cases of NTD appear resistant to folic acid. In the randomized controlled trial of the Medical Research Council, UK (Wald et al., 1991) , 28% of NTD cases recurred despite supplementation with 4 mg folic acid per day. Moreover, the recent introduction of folic acid fortification of bread flour in the USA resulted in only a 19% decline in the prevalence of NTDs (Honein et al., 2001) . While these findings may indicate the need for increased levels of folic acid supplementation, they are also consistent with a proportion of NTDs exhibiting resistance to exogenous folic acid.
Mouse genetic models also indicate the existence of folateresistant NTDs. Mutant strains including 'splotch', 'crooked tail' and the 'Cart1' knockout exhibit NTDs that can be prevented by folic acid treatment during early pregnancy (Fleming and Copp, 1998; Zhao et al., 1996; Carter et al., 1999) , whereas folic acid is ineffective in preventing NTDs in the mutant strains 'curly tail', 'axial defects' and the 'ephrin-
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A5' knockout (Essien and Wannberg, 1993; Seller, 1994; Holmberg et al., 2000) .
Previously, it was demonstrated that a proportion of the folate-resistant NTDs in curly tail mice can be prevented by treating pregnant females, or embryos in vitro, with myoinositol (Greene and Copp, 1997) . These findings were consistent with earlier work showing that deficiency of myo-inositol in the culture medium of rat and mouse embryos caused a high incidence of cranial NTDs (Cockroft, 1988; Cockroft et al., 1992) , and that NTDs developing in rat embryos cultured under diabetic conditions could be ameliorated by supplementation with myo-inositol (Baker et al., 1990; Hashimoto et al., 1990) . Together, these findings suggest inositol as a potential therapeutic option for prevention of folate-resistant NTDs.
Here, the analysis of inositol as a primary therapeutic agent in preventing mouse NTDs has been extended. The study was intended to serve as a preliminary to a human clinical therapeutic trial. It was shown that inositol could prevent NTDs both in vitro and following administration to pregnant curly tail females, either by s.c. or oral routes. A detailed pathological analysis revealed no significant adverse effects of inositol therapy on mouse fetuses. Moreover, the effectiveness of myo-inositol was compared with that of D-chiro-inositol, a closely related enantiomer that differs in the orientation of the carbon-two hydroxyl group (C2-OH) relative to the plane of the six carbon ring.
Materials and methods
Mice
Curly tail mice are maintained as a homozygous, random-bred stock in which NTDs develop in~60% of individuals (Van Straaten and Copp, 2001) . Experimental litters were generated by timed matings, and the day of finding a copulation plug was designated embryonic day (E) 0.5.
In-vitro inositol treatment E9.5 embryos (17-19 somite stage) were cultured for 24 h at 38°C in whole rat serum, as described previously (Copp et al., 1999) . At 30 min after the start of culture, myo-inositol (Sigma, UK) or D-chiroinositol (Insmed, VA, USA) was added to the medium (62.5 µl of inositol stock per ml rat serum) to a final concentration of 5, 10, 20 or 50 µg/ml inositol. Control cultures received an equal volume of phosphate-buffered saline (PBS). Following culture, embryos were scored for: (i) posterior neuropore length (the distance from the rostral end of the posterior neuropore to the tip of the tail bud); (ii) crownrump length; and (iii) somite number.
In-utero inositol treatment
For s.c. administration, osmotic mini-pumps (capacity 100 µl, delivery rate 1 µl/h; model 1003D, Alzet) were filled with solutions of 30, 75 or 150 mg/ml inositol (delivering 29, 72 and 144 µg inositol/g body weight per day respectively for a 25 g mouse), or PBS as a control. Mini-pumps were incubated in sterile PBS at 37°C for 4 h and then implanted s.c. on the back of pregnant mice at E8.5. General anaesthesia was induced by an i.p. injection of 0.01 ml/g body weight of a solution comprising 10% Hypnovel ® (midazolam 5 mg/ml) and 25% Hypnorm ® (fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml) in sterile distilled water. For oral administration, pregnant mice were gavaged with 0.5 ml inositol solution in PBS twice daily intervals from E8.5 to E10.5 (six doses in total; 800 µg/g body weight per day).
Analysis of fetuses following inositol treatment in utero
Pregnant females were killed at E18.5, and the total number of implantations, classified as viable fetuses or resorptions, was recorded. Fetuses were dissected from the uterus and inspected immediately for the presence of open lumbo-sacral spina bifida and tail flexion defects: the primary manifestations of the curly tail genetic defect (Gruneberg, 1954; Van Straaten and Copp, 2001) . A randomly selected sample of fetuses was fixed in Bouin's fluid and subjected to detailed internal pathological analysis by free-hand serial sectioning (Wilson, 1965) . Other fetuses were fixed in 95% ethanol and processed for skeletal examination (Whittaker and Dix, 1979) .
Statistical data analysis
Continuous variables (somite number, crown-rump length, posterior neuropore length, litter size) were compared between treatment groups using analysis of variance or Kruskal-Wallis test. Ordinal regression was used to quantify further the effects of treatment and dosage on posterior neuropore length. Fisher's exact or χ 2 -tests were used to compare phenotype frequencies between groups. To evaluate possible 2452 litter effects, multilevel ordinal logistic models were fitted to the data in Table III (MLwiN v1.10.0006) (Goldstein, 1995) . Logistic regression was used to determine whether the number of resorptions in utero was linked to dose and/or treatment.
Results
D-chiro-inositol is more effective than myo-inositol in normalizing neural tube closure in embryo culture
Curly tail embryos were cultured in the presence of inositol for 24 h from E9.5, the period during which the neural tube is closing at the posterior neuropore of the mouse embryo. In curly tail embryos, neuropore closure is delayed or fails to be completed, leading to the development of tail flexion defects and spina bifida, respectively ( Figure 1A-C) (Copp, 1985) . Posterior neuropore length at E10-10.5 is positively correlated with the likelihood that an embryo will progress to develop a spinal NTD (Copp, 1985; Van Straaten et al., 1992) .
Both myo-and D-chiro-inositol exhibited a dose-dependent normalization of posterior neuropore length in embryo culture, as judged by the reduction in neuropore length observed in embryos treated with higher inositol doses (Table I; Figure  2A ). Strikingly, D-chiro-inositol significantly reduced neuropore length at dose levels of both 20 and 50 µg/ml, whereas a comparable effect was seen with myo-inositol only at 50 µg/ml. Embryos exposed to 20 µg/ml myo-inositol (or 5-10 µg/ml D-chiro-inositol) exhibited neuropore lengths that were not different from PBS-treated controls.
Neither myo-nor D-chiro-inositol affect the rate of embryonic growth in embryo culture
In the experimental design, embryos in the different treatment groups were matched for somite number before culture, in order to avoid differences in developmental outcome (neuropore length) that might arise from comparing embryos of different stages. Following culture, all groups exhibited mean somite numbers in the range 30-31, with no difference between treatments (Table I) . Moreover, no significant difference was found in crown-rump length of embryos treated with either myo-or D-chiro-inositol compared with PBS-treated controls ( Table I ), suggesting that the effect of inositol is specific to the closing posterior neuropore, and not mediated via alteration of embryonic growth.
D-chiro-inositol is more effective than myo-inositol in preventing NTDs in utero
Next, the effectiveness of s.c. and oral routes of inositol administration in preventing NTDs in curly tail litters was evaluated. Using surgically implanted osmotic mini-pumps to administer inositol at a constant rate over a period of 72 h of pregnancy, encompassing the stages of neural tube closure, a dose-dependent effect of both myo-and D-chiro-inositol was observed. At 29 µg/g body weight per day, neither myo-nor D-chiro-inositol significantly affected the frequency of fetuses with spina bifida ( Figure 2B ), whereas at dose levels of 72 and 144 µg/g body weight per day, both inositols reduced the frequency of spina bifida compared with PBS-treated pregnancies ( Figure 2B ). At these higher dose levels, inositol , the fetus with spina bifida (E) exhibits vertebral pedicles widely spaced apart and absent neural arches in the low lumbar/sacral region (long arrow in E). The tail (short arrow in E) is enclosed in a skin sac and appears reduced in length owing to deformation and fusion of caudal vertebrae. The tail flexion defect (G) comprises a 360°curl of the tail, compared with the normal fetus which exhibits a straight tail (F). Scale bars: A ϭ 0.5 mm; B,C ϭ 0.2 mm; D,E ϭ 2 mm; F,G ϭ 2 mm. caused a significant shift towards the mild end of the NTD phenotype spectrum, with fewer fetuses having spina bifida and more appearing normal (Table II) . As with the in-vitro 2453 study, D-chiro-inositol appeared most effective, causing a 73-83% decrease in spina bifida frequency relative to PBS controls, at both 72 and 144 µg/g body weight per day. Statistical analysis: somite number and crown-rump length do not differ significantly, whereas posterior neuropore (PNP) length varies significantly between treatment groups (P Ͻ 0.0001). Ordinal regression analysis indicates that PNP length is significantly reduced (marked with asterisk) in embryos treated with myo-inositol (50 µg/ml) and D-chiro-inositol (20 and 50 µg/ml) compared with those exposed to phosphatebuffered saline (PBS) alone (P Ͻ 0.05), whereas PNP length in other inositol-treated groups does not differ significantly from the PBS control group.
Myo-inositol produced a consistent 54-56% reduction in spina bifida frequency ( Figure 2B ). Inositol was administered orally to pregnant females, using a twice-daily dosing regime, from E8.5 to E10.5, that delivered 800 µg/g body weight per day, equivalent to the i.p. dose used in a previous study (Greene and Copp, 1997 ). As with s.c. administration, a marked reduction was detected in the frequency of spina bifida among the offspring of mice treated with either myo-or D-chiro-inositol ( Figure 2B) , and a significant shift in the distribution of fetuses between the three phenotype categories (Table II) . D-chiro-inositol was most effective, causing a 86% reduction in the frequency of spina bifida, while a 53% reduction was observed for myo-inositol.
An ordinal multilevel regression analysis confirmed that fetuses treated s.c. with D-chiro-inositol (P Ͻ 0.0005) and myo-inositol (P Ͻ 0.002) were significantly less likely to have spina bifida than those treated with PBS. In the oral dosing study, fetuses treated with D-chiro-inositol were less likely to have spina bifida than PBS-treated controls (P Ͻ 0.01), whereas the trend towards reduced spina bifida frequency in litters treated with myo-inositol did not reach statistical significance.
A further investigation was made to determine whether clustering of fetuses of particular phenotypes within litters may have affected the outcome of the comparison between myo-inositol, D-chiro-inositol and PBS. The multilevel analysis (which took into account the potential non-independence of fetuses within litters) showed that the difference between treatment groups is unaffected when possible litter effects are taken into account.
No evidence of an adverse effect of inositol on pregnancy success or fetal outcome
One possible explanation for a decrease in spina bifida frequency following maternal inositol administration could be an increase in loss of affected fetuses during pregnancy. When both resorption rate and litter size were examined in pregnancies receiving either s.c. or oral inositol, no significant 2454 difference was found between pregnancies treated with inositol and those receiving PBS alone (Table III) .
To identify any adverse effects of inositol treatment on fetal outcome, fetal crown-rump length was measured, but no significant differences were found between treatment groups (Table III) . An extensive pathological analysis of treated fetuses was performed using both free-hand serial sectioning and skeletal preparation. This analysis confirmed the occurrence of spina bifida and tail defects in a proportion of fetuses ( Figure 1D-G) , as also scored by external fetal inspection. Additionally, exencephaly, a failure of cranial neural tube closure, was observed in a small proportion of fetuses (Table  IV) . Exencephaly is a recognized, infrequent defect in curly tail homozygotes (Embury et al., 1979) . No overall increase or decrease in this defect was observed in inositol-treated fetuses compared with PBS controls, although the low frequency of affected fetuses may have obscured any treatment effect.
Internal and skeletal examination revealed almost no major structural defects, apart from NTDs (Table IV) . For instance, no major malformations of the heart, lungs, kidney, gut, limbs or skeleton were identified. Of the morphological changes observed in the analysis, most were minor (e.g. small additional liver lobe) and the great majority occurred as frequently in PBS controls as in fetuses treated with inositol. D-chiroinositol-treated fetuses (144 µg/g body weight per day) showed a somewhat elevated frequency of enlargement of the renal pelvis/ureter, rudimentary ribs on the seventh cervical vertebra and occurrence of anomalous cervical vertebrae (Table IV) , although these trends were not statistically significant. Anomalous cervical vertebrae was associated with exencephaly in several litters, suggesting that cervical anomalies may form part of the spectrum of vertebral column defects present in the curly tail mouse.
Discussion
In the present study, the ability of exogenous inositol to prevent spinal NTDs in the folate-resistant curly tail mouse genetic Embryos treated with phosphate-buffered saline (PBS) (light grey bar; n ϭ 16), 20 µg/ml myo-inositol (n ϭ 16), or 5-10 µg/ml D-chiro-inositol (n ϭ 15 in each group) all exhibit mean neuropore lengths of~0.6 mm, evidence of delayed posterior neuropore closure. Treatment with 50 µg/ml myo-inositol (n ϭ 16) or 20-50 µg/ml D-chiro-inositol (n ϭ 18 and 15 respectively) significantly reduced (P Ͻ 0.05) mean neuropore length to values typical of non-mutant embryos at this somite stage. (B) Administration of myo-or D-chiro-inositol to pregnant curly tail females by slow release from s.c. implanted minipumps reduces the frequency of spina bifida at doses of 72 and 144 µg/g body weight per day, but not at 29 µg/g body weight per day. A similar preventive effect of inositol is seen with oral dosing at 800 µg/g body weight per day. For results of statistical analysis, see text.
model was evaluated. Maternal inositol administration significantly reduced the frequency of spina bifida in curly tail mice and normalized closure of the posterior neuropore in whole cultured embryos. A striking finding was the increased potency of D-chiro-inositol compared with myo-inositol-two closely related enantiomers that differ only in the orientation of the carbon-two hydroxyl group (C2-OH) relative to the plane of the six carbon ring. At identical dosage levels, s.c. administered D-chiro-inositol caused a consistently greater reduction in frequency of spina bifida than myo-inositol. Moreover, in vitro, D-chiro-inositol was effective in normaliz-2455 ing neural tube closure at a concentration at which myo-inositol had no effect.
Reasons for the differing potency of myo-and D-chiroinositol in preventing NTD
It was shown previously that the protective effect of myoinositol is mediated via the phosphoinositide cycle (Greene and Copp, 1997) , which generates the second messengers inositol triphosphate and diacylglycerol (DAG) (Majerus, 1992) . Among the downstream events of this signalling pathway, activation of protein kinase C (PKC) by DAG appears critical for normalization of neuropore closure in curly tail embryos. For instance, activation of PKC by phorbol esters mimics the effect of inositol supplementation, whereas PKC inhibitors abrogate the protective effect (Greene and Copp, 1997) .
It is possible that D-chiro-inositol also acts through a PKCdependent pathway, in which case the greater preventive effect of D-chiro-inositol may result from its differential incorporation and metabolism within the phosphoinositide cycle. Insulin stimulation of rat fibroblasts expressing the human insulin receptor leads to a significant increase in the incorporation of D-chiro-inositol into phospholipids, whereas the effect on myo-inositol incorporation is only marginal (Pak et al., 1993) . Moreover, D-chiro-inositol induces a much larger reduction in plasma glucose level in rats rendered diabetic by streptozotocin administration compared with exogenous myoinositol (Ortmeyer et al., 1993) . In humans, D-chiro-inositol can increase the action of insulin in patients with polycystic ovarian syndrome, improving ovulatory function, reducing blood pressure, and decreasing blood androgen and triglyceride concentrations (Nestler et al., 1999) . These findings suggest an inherently greater potency or bioactivity of D-chiro-inositol than myo-inositol, perhaps as a result of incorporation into different phosphatidylinositol species . It is striking, however, that these differences of in-vivo potency are maintained in the face of the demonstrated interconversion of the two inositol isomers . Perhaps the rate of interconversion is too low to obscure the inherently greater potency of D-chiro-inositol in short-term effects on embryonic development.
How does inositol normalize neural tube closure in curly tail mice?
Although the causative gene responsible for the curly tail defect is unknown (Van Straaten and Copp, 2001) , the primary cellular abnormality leading to the development of spina bifida has been identified as a reduced rate of cell proliferation in the hindgut endoderm and notochord (Copp et al., 1988) . The resultant growth imbalance between dorsal and ventral tissues causes excessive ventral curvature of the caudal embryonic region, which mechanically opposes closure of the posterior neuropore (Brook et al., 1991) . Exogenous inositol treatment may correct the underlying cell proliferation defect in curly tail embryos. In support of this idea, inositol metabolism is known to be intimately involved with cell cycle progression in a variety of cell types. For instance, a nuclear polyphosphoinositide cycle exists in which phosphatidylinositol-specific a µg inositol/g body weight per day. b Phenotype frequencies expressed as number of fetuses (% of total for treatment group). c Statistical analysis: distribution of embryos among the three phenotype categories varies significantly with treatment group at 72, 144 and 800 µg inositol/g body weight per day (χ 2 -tests, P ϭ 0.0005, 0.0051 and 0.026 respectively) but not at 29 µg inositol/g body weight per day (P ϭ not significant). PBS ϭ phosphate-buffered saline. phospholipase C generates elevated levels of nuclear DAG specifically during G 2 phase of the cell cycle (Sun et al., 1997) . This DAG production is required for the G 2 /M transition, perhaps by attracting specific activated PKC isozymes to the nucleus, where they are stabilized by binding to nuclear proteins including lamins A, B and C. The elevation of DAG levels is transient, as DAG is rapidly converted to phosphatidic acid by nuclear DAG kinases, enzymes that are also induced by growth-promoting agents (Martelli et al., 2000) . It is possible that inositol treatment of curly tail embryos stimulates this nuclear DAG cycle leading, via the activation of specific PKC isozymes, to the increased proliferation of hindgut and notochordal cells, so normalizing neural tube closure.
Relevance of the findings for clinical application of inositol therapy
In order for these experimental findings to be translated into a clinical application, inositol supplementation must be not only effective in preventing NTDs, but also safe for use during human pregnancy. The current demonstration of a protective effect of inositol by s.c. and oral administration is supported by the results of previous studies in which myo-inositol was injected i.p. (Greene and Copp, 1997) . Further support for the effectiveness of oral supplementation with myo-inositol comes from the finding of a reduction in the incidence of diabetesinduced abnormalities in rats by oral administration of myoinositol (Khandelwal et al., 1998) . The efficacy of inositol in preventing human NTDs has not yet been tested in a clinical trial. Nevertheless, a recent case study has documented inositol supplementation in association with a normal outcome in the third pregnancy of a woman who had two previous consecutive NTD pregnancies despite taking 4 mg folic acid throughout the periconceptional period (Cavalli and Copp, 2002) . The empirical recurrence risk of NTD following two previous affected fetuses is~1 in 9 (Seller, 1981) , so the association of inositol therapy with normal pregnancy outcome in this case may have been a chance association. A larger study of pregnancies at risk of 'folate-resistant' NTDs is needed, to test the idea that inositol may be as effective in humans as in mice.
With regard to the safety of inositol therapy during pregnancy, the present pathological study revealed no major defects, apart from NTDs, and no increase in the frequency of embryonic or fetal loss in utero in inositol-treated mice. The present study was limited, however, and in particular the effects of inositol administration during the periconceptional periodwhen inositol would be taken during a clinical trial-were not assessed. The reproductive toxicology of D-chiro-inositol has 2457 been the subject of studies in rats and rabbits, with more extensive administration at doses up to 2000 mg/kg per day, and no adverse effects on mating, fertility or embryo/fetal development have been found (Insmed Inc., data on file). There is much less information available on the safety of inositol therapy in human pregnancy. In the case of the mother who took inositol in her third pregnancy following two apparently 'folate-resistant' NTD pregnancies, a dose of 0.5 g inositol per day was used, with no known side-effects for either mother or baby (Cavalli and Copp, 2002) . In particular, there was no evidence of abnormal uterine contractions, such as have been suggested as a possible adverse effect of inositol therapy (Colodny and Hoffman, 1998) . Myo-inositol has also been tested in adults for prevention of depression, panic disorder and obsessive compulsive disorder (Benjamin et al., 1995; Levine et al., 1995; Fux et al., 1996) and in children for treatment of autism (Levine et al., 1997) . No significant side-effects were reported in these studies, which employed relatively high inositol doses of up to 18 g per day in adults and 200 mg/kg in children.
In conclusion, D-chiro-inositol has been shown to be highly effective in preventing folate-resistant mouse NTDs. A clinical trial could next evaluate the effectiveness of peri-conceptional inositol supplementation, as an adjunct to folic acid therapy, in preventing human NTDs. If folate-resistant NTDs can be prevented, in addition to those cases already prevented by folic acid, this could lead to a significant further reduction in the frequency of this birth defect.
